Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, is scheduled to present at two events in June:
1. Jefferies Healthcare Conference in New York, NY on June 7, 2023, at 3:00 pm EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on June 13, 2023, at 3:20 pm PDT
Both presentations will be available via webcast. Interested parties can access the webcasts through the Events page on Caribou's website. The recordings will remain accessible for 30 days after each event.
Caribou Biosciences (Nasdaq: CRBU), una delle principali aziende biofarmaceutiche in fase clinica specializzata nell'editing genomico CRISPR, ha annunciato la sua partecipazione a prossimi convegni per investitori. Rachel Haurwitz, PhD, presidente e CEO dell'azienda, è prevista come relatrice in due eventi a giugno:
1. Jefferies Healthcare Conference a New York, NY il 7 giugno 2023, alle 15:00 EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference a Dana Point, CA il 13 giugno 2023, alle 15:20 PDT
Entrambe le presentazioni saranno disponibili tramite webcast. Le parti interessate possono accedere ai webcast attraverso la pagina Eventi sul sito web di Caribou. Le registrazioni rimarranno accessibili per 30 giorni dopo ciascun evento.
Caribou Biosciences (Nasdaq: CRBU), una de las principales empresas biofarmacéuticas en etapa clínica que se especializa en la edición de genomas con CRISPR, ha anunciado su participación en próximas conferencias de inversionistas. Rachel Haurwitz, PhD, presidenta y CEO de la empresa, está programada para presentar en dos eventos en junio:
1. Jefferies Healthcare Conference en Nueva York, NY el 7 de junio de 2023, a las 3:00 pm EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference en Dana Point, CA el 13 de junio de 2023, a las 3:20 pm PDT
Ambas presentaciones estarán disponibles a través de webcast. Las partes interesadas pueden acceder a los webcasts a través de la página de Eventos en el sitio web de Caribou. Las grabaciones permanecerán accesibles durante 30 días después de cada evento.
Caribou Biosciences (Nasdaq: CRBU)는 선도적인 임상 단계 CRISPR 유전자 편집 생명공학 회사로서 다가오는 투자자 회의에 참여한다고 발표했습니다. Rachel Haurwitz, PhD, 회사의 사장 겸 CEO가 6월에 두 개의 행사에서 발표할 예정입니다:
1. Jefferies Healthcare Conference가 2023년 6월 7일 뉴욕, NY에서 오후 3:00 EDT에 개최됩니다.
2. Goldman Sachs 제44회 연례 글로벌 헬스케어 회의가 2023년 6월 13일 Dana Point, CA에서 오후 3:20 PDT에 개최됩니다.
두 발표 모두 웹캐스트를 통해 제공됩니다. 관심 있는 분들은 Caribou의 웹사이트의 이벤트 페이지를 통해 웹캐스트에 접근할 수 있습니다. 녹화된 자료는 각 행사 후 30일 동안 접근 가능합니다.
Caribou Biosciences (Nasdaq: CRBU), une entreprise biopharmaceutique de premier plan dans le domaine de l'édition génomique par CRISPR, a annoncé sa participation à des conférences pour investisseurs à venir. Rachel Haurwitz, PhD, présidente et PDG de l'entreprise, est prévue pour présenter lors de deux événements en juin :
1. Jefferies Healthcare Conference à New York, NY, le 7 juin 2023, à 15h00 EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference à Dana Point, CA, le 13 juin 2023, à 15h20 PDT
Les deux présentations seront disponibles par webinaire. Les parties intéressées peuvent accéder aux webinaires via la page Événements sur le site internet de Caribou. Les enregistrements resteront accessibles pendant 30 jours après chaque événement.
Caribou Biosciences (Nasdaq: CRBU), ein führendes biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die CRISPR-Genom-Editierung spezialisiert hat, hat seine Teilnahme an bevorstehenden Investorenkonferenzen bekannt gegeben. Rachel Haurwitz, PhD, die Präsidentin und CEO des Unternehmens, wird bei zwei Veranstaltungen im Juni präsentieren:
1. Jefferies Healthcare Conference in New York, NY am 7. Juni 2023 um 15:00 Uhr EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA am 13. Juni 2023 um 15:20 Uhr PDT
Beide Präsentationen werden über Webcast verfügbar sein. Interessierte Parteien können die Webcasts über die Veranstaltungsseite auf der Website von Caribou abrufen. Die Aufzeichnungen werden 30 Tage nach jeder Veranstaltung zugänglich bleiben.
- None.
- None.
BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present at the following investor conferences during the month of June:
- Jefferies Healthcare Conference, New York, NY
June 7, 2023, 3:00 pm EDT
Webcast - Goldman Sachs 44th Annual Global Healthcare Conference, Dana Point, CA
June 13, 2023, 3:20 pm PDT
Webcast
For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.
About Caribou’s Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems have exhibited editing at unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. Contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
FAQ
Which investor conferences will Caribou Biosciences (CRBU) attend in June 2023?
Who will be presenting on behalf of Caribou Biosciences (CRBU) at the upcoming investor conferences?
How can investors access the Caribou Biosciences (CRBU) presentations at the June 2023 conferences?
What is the focus area of Caribou Biosciences (CRBU)?
